EUVIMEDEUVIMED entdecken
Multizentrische Studie

Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study

Joanna A Krupka iD, Ilias Moutsopoulos iD, Natasha H Cutmore iD, Christopher S Trethewey iD, Alimu Dayimu iD, Rebecca Goodhew iD, Furqaan Kaji, Livia Raso-Barnett iD, Heok Cheow, Lee Elzubeir, Julie Smith, Anver Kamil und 19 weitere

Journal of Clinical Oncology · 10.02.2026 · 44 (5) · 410-420

DOI: 10.1200/jco-25-01587 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2026. Verfasst von Joanna A Krupka und 30 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) allows ultrasensitive detection of minimal residual disease (MRD) that may enhance the accuracy of response assessment. Previous studies have been constrained by small cohort size, retrospective design, or assays limited to a single commercial provider. PATIENTS AND METHODS DIRECT was a prospective, multisite study evaluating the utility of ctDNA in patients with LBCL. We developed a lymphoma-customized, open-source, ctDNA assay and pipeline that captured hundreds of PVs per patient. Using landmark analysis, we evaluated the prognostic impact of PV-supported MRD at the end of first-line therapy (EoT). RESULTS EoT PV-MRD status was available for 155 patients. After a median of 24.5 months, 2-year time to tumor progression (TTP) for patients with detectable versus undetectable PV-MRD was 42% versus 95%, respectively ( P < .001; hazard ratio [HR], 13.7). When restricted to patients receiving full-dose anthracycline-based immunochemotherapy, 2-year TTP was 45% versus 96%, respectively ( P < .001; HR, 15.4), outperforming conventional radiological response assessment (HRs, 6.9 for positron emission tomography v 16.9 for PV-MRD). The limit of detection with 95% confidence (LoD95) varied by more than two orders of magnitude across patients, underscoring the need to report patient-specific LoD95. Persistent PV-MRD in the absence of relapse was noted, including three of four patients with transformed follicular lymphoma, highlighting a potential caveat when interpreting positive PV-MRD . CONCLUSION EoT PV-MRD enables sensitive and clinically meaningful response assessment in LBCL. It provides independent prognostic information, enhancing EoT response assessment beyond conventional radiologic assessment. Our findings support the incorporation of PV-MRD into clinical trials and routine management of diffuse LBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphoma, Large B-Cell, DiffuseBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedProspective StudiesAgedPrognosisAdultNeoplasm, ResidualAged, 80 and over

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Department of Haematology, University of Cambridge, Cambridge, UK.
  • Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, UK.
  • Cambridge Clinical Trials Unit-Cancer Theme, University of Cambridge, Cambridge, UK.
  • Department of Haematology, Cambridge University Hospitals Foundation Trust, Cambridge, UK.
  • Haemato-Oncology Diagnostic Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.

ORCID-Profile: Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore, Christopher S Trethewey, Alimu Dayimu, Rebecca Goodhew, Livia Raso-Barnett, Philip Barry, Martin G Thomas, Duane Hassane, Matthew Ahearne, Christopher P Fox, Daniel J Hodson

Zitieren

APA

Krupka, J. A., Moutsopoulos, I., Cutmore, N. H., Trethewey, C. S., Dayimu, A., Goodhew, R., Kaji, F., Raso-Barnett, L., Cheow, H., Elzubeir, L., Smith, J., Kamil, A., Barbara, R. R., Price, J., Elston, K., Kolodziejczyk, A., Tarantino, S., Mariscotti, F., Barry, P., …, & Hodson, D. J. (2026). Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. Journal of Clinical Oncology, 44(5), 410-420. https://doi.org/10.1200/jco-25-01587

Vancouver

Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, et al. Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. Journal of Clinical Oncology. 2026;44(5):410-420. doi:10.1200/jco-25-01587

BibTeX
@article{Krupka2026,
  author = {Krupka, Joanna A and Moutsopoulos, Ilias and Cutmore, Natasha H and Trethewey, Christopher S and Dayimu, Alimu and Goodhew, Rebecca and Kaji, Furqaan and Raso-Barnett, Livia and Cheow, Heok and Elzubeir, Lee and Smith, Julie and Kamil, Anver and Barbara, Ramona-Rita and Price, Jane and Elston, Kay and Kolodziejczyk, Aleksandra and Tarantino, Silvia and Mariscotti, Fabiana and Barry, Philip and Frost, Steven and Demiris, Nikolaos and Thomas, Martin G and Hassane, Duane and Munugalavadla, Veerendra and Nagumantry, Sateesh Kumar and Karanth, Mamatha J and Ahearne, Matthew and Shah, Nimish and Fox, Christopher P and Anand, Shubha and Hodson, Daniel J},
  title = {Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {410--420},
  doi = {10.1200/jco-25-01587}
}
Kostenlos starten →